E

Winner, winner, chicken dinner!

5 key and novel early areas of development which stood out to us at AACR22

April 11, 2022
E

A high level view of the latest Target Protein Degradation data

What's the skinny on C4 Therapeutics and other TPD programs at AACR and ASCO?

May 16, 2022
E

Watch to watch out for at ASCO22

Hot or not - 5 early stage trials with different agents and targets

May 5, 2022
E

Take the high road

5 abstracts to watch out for at the ASCO22 meeting in Chicago

May 2, 2022
E

Revelations

New CAR-T cell developments in solid tumours - hit or miss?

April 24, 2022
E

An inconvenient truth

Looking beyond the hype from a broader perspective

April 18, 2022
E

AACR22 Part 2 of the RASpalooza

Highlights from the KRAS front with three different company products not named sotorasib or adagrasib

April 13, 2022
E

An explosion of new opportunities in the expanding KRAS landscape

Going beyond both G12C and G12D to a plethora of new targets and combination approaches

April 10, 2022
E

Addressing acquired resistance through novel combination strategies

All aboard to hear more about novel targeted therapy combination strategies...

April 8, 2022
E

Discovering novel oncogenic targets

Finding new synthetic lethal targets to induce more potent cell death and improve outcomes

April 8, 2022
E

Off the beaten track in the bispecific landscape

Everything you needed to know about bispecifics at AACR22 and more!

March 31, 2022
E

What to watch at AACR22 on NK cells

What to watch out for at AACR22 if you're interested in NK cells

March 29, 2022
E

5 important topics to watch out for at AACR22 on bispecifics

5 areas to watch out for on the bispecific antibody front

March 25, 2022
E

New directions and opportunities with intractable oncology targets

Just because a pathway has been called undruggable doesn't always mean it will be so!

March 15, 2022
E

AACR22 Preview 1 – Key topics to watch out for

Hot topics to follow at AACR22

March 7, 2022